Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.

Lu Y, Boswell W, Boswell M, Klotz B, Kneitz S, Regneri J, Savage M, Mendoza C, Postlethwait J, Warren WC, Schartl M, Walter RB.

Sci Rep. 2019 Jan 24;9(1):530. doi: 10.1038/s41598-018-36656-x.

2.

In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia.

McGuffin SA, Bharadwaj R, Gonzalez-Cuyar LF, Schiffer JT, Stacey AW, Walter RB, Duke ER.

Clin Infect Dis. 2019 Jan 18;68(3):525-529. doi: 10.1093/cid/ciy394. No abstract available.

PMID:
30657904
3.

Outpatient induction and consolidation care strategies in acute myeloid leukemia.

Halpern AB, Walter RB, Estey EH.

Curr Opin Hematol. 2019 Mar;26(2):65-70. doi: 10.1097/MOH.0000000000000481.

PMID:
30585894
4.

CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia.

Halpern AB, Walter RB.

Oncotarget. 2018 Nov 27;9(93):36543-36544. doi: 10.18632/oncotarget.26383. eCollection 2018 Nov 27. No abstract available.

5.

Refining AML outcome prediction.

Hourigan CS, Gale RP, Walter RB.

Leukemia. 2019 Feb;33(2):283-284. doi: 10.1038/s41375-018-0317-4. Epub 2018 Dec 14. No abstract available.

PMID:
30552400
6.

Long-term experimental hybridisation results in the evolution of a new sex chromosome in swordtail fish.

Franchini P, Jones JC, Xiong P, Kneitz S, Gompert Z, Warren WC, Walter RB, Meyer A, Schartl M.

Nat Commun. 2018 Dec 3;9(1):5136. doi: 10.1038/s41467-018-07648-2.

7.

Phase 1/2 trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2018 Nov 8. pii: haematol.2018.204792. doi: 10.3324/haematol.2018.204792. [Epub ahead of print]

8.

Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.

Morsink LM, Walter RB, Ossenkoppele GJ.

Blood Rev. 2018 Nov 1. pii: S0268-960X(18)30072-9. doi: 10.1016/j.blre.2018.10.003. [Epub ahead of print] Review.

PMID:
30401586
9.

Workshop report: Cryopreservation of aquatic biomedical models.

Hagedorn M, Varga Z, Walter RB, Tiersch TR.

Cryobiology. 2019 Feb;86:120-129. doi: 10.1016/j.cryobiol.2018.10.264. Epub 2018 Oct 31.

PMID:
30389588
10.

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.

Othus M, Estey EH, Garcia-Manero G, Wood BL, Stirewalt DL, Godwin JE, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2019 Feb;33(2):554-558. doi: 10.1038/s41375-018-0274-y. Epub 2018 Oct 12. No abstract available.

PMID:
30315233
11.

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.

Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo RR, Kiem HP, Walter RB.

Leukemia. 2018 Oct 5. doi: 10.1038/s41375-018-0277-8. [Epub ahead of print] No abstract available.

PMID:
30291334
12.

A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Buckley SA, Percival ME, Othus M, Halpern AB, Huebner EM, Becker PS, Shaw C, Shadman M, Walter RB, Estey EH.

Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1516036. [Epub ahead of print]

PMID:
30277112
13.

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.

Klupsch K, Baeriswyl V, Scholz R, Dannenberg J, Santimaria R, Senn D, Kage E, Zumsteg A, Attinger-Toller I, von der Bey U, König-Friedrich S, Dupuy F, Lembke W, Albani C, Wendelspiess S, Dinkel L, Saro D, Hepler RW, Laszlo GS, Gudgeon CJ, Bertschinger J, Brack S, Walter RB.

Leukemia. 2018 Sep 11. doi: 10.1038/s41375-018-0249-z. [Epub ahead of print] No abstract available.

PMID:
30206306
14.

Analysis of the putative tumor suppressor gene cdkn2ab in pigment cells and melanoma of Xiphophorus and medaka.

Regneri J, Klotz B, Wilde B, Kottler VA, Hausmann M, Kneitz S, Regensburger M, Maurus K, Götz R, Lu Y, Walter RB, Herpin A, Schartl M.

Pigment Cell Melanoma Res. 2018 Aug 16. doi: 10.1111/pcmr.12729. [Epub ahead of print]

PMID:
30117276
15.

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.

Laszlo GS, Beddoe ME, Godwin CD, Bates OM, Gudgeon CJ, Harrington KH, Walter RB.

Haematologica. 2019 Feb;104(2):e59-e62. doi: 10.3324/haematol.2018.202069. Epub 2018 Aug 16. No abstract available.

16.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.

Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25.

PMID:
30045838
17.

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML).

Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, Kanaan M, Estey EH.

J Drug Assess. 2018 Jul 10;7(1):51-53. doi: 10.1080/21556660.2018.1492925. eCollection 2018.

18.

Evaluating measurable residual disease in acute myeloid leukemia.

Ravandi F, Walter RB, Freeman SD.

Blood Adv. 2018 Jun 12;2(11):1356-1366. doi: 10.1182/bloodadvances.2018016378. Review.

19.

Next-generation sequencing for measuring minimal residual disease in AML.

Walter RB, Appelbaum FR.

Nat Rev Clin Oncol. 2018 Aug;15(8):473-474. doi: 10.1038/s41571-018-0040-0. No abstract available.

PMID:
29795270
20.

Waveband specific transcriptional control of select genetic pathways in vertebrate skin (Xiphophorus maculatus).

Walter RB, Boswell M, Chang J, Boswell WT, Lu Y, Navarro K, Walter SM, Walter DJ, Salinas R, Savage M.

BMC Genomics. 2018 May 10;19(1):355. doi: 10.1186/s12864-018-4735-5.

21.

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Apr 17. doi: 10.1038/s41375-018-0135-8. [Epub ahead of print]

22.

Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

Michaelis LC, Klepin HD, Walter RB.

Expert Opin Pharmacother. 2018 Jun;19(8):865-882. doi: 10.1080/14656566.2018.1465562. Epub 2018 Apr 26. Review.

PMID:
29697000
23.

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.

Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1615-1620. doi: 10.1016/j.bbmt.2018.04.017. Epub 2018 Apr 21.

PMID:
29684564
24.

Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?

Walter RB.

J Clin Oncol. 2018 May 20;36(15):1463-1465. doi: 10.1200/JCO.2018.78.3266. Epub 2018 Apr 6. No abstract available.

PMID:
29624462
25.

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.

Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, Gudgeon CJ, Bates OM, Olson JM, Mehlin C, Walter RB.

Leukemia. 2018 May;32(5):1239-1243. doi: 10.1038/s41375-018-0014-3. Epub 2018 Jan 31. No abstract available.

26.

Investigational CD33-targeted therapeutics for acute myeloid leukemia.

Walter RB.

Expert Opin Investig Drugs. 2018 Apr;27(4):339-348. doi: 10.1080/13543784.2018.1452911. Epub 2018 Mar 15. Review.

PMID:
29534618
27.

Clonal polymorphism and high heterozygosity in the celibate genome of the Amazon molly.

Warren WC, García-Pérez R, Xu S, Lampert KP, Chalopin D, Stöck M, Loewe L, Lu Y, Kuderna L, Minx P, Montague MJ, Tomlinson C, Hillier LW, Murphy DN, Wang J, Wang Z, Garcia CM, Thomas GCW, Volff JN, Farias F, Aken B, Walter RB, Pruitt KD, Marques-Bonet T, Hahn MW, Kneitz S, Lynch M, Schartl M.

Nat Ecol Evol. 2018 Apr;2(4):669-679. doi: 10.1038/s41559-018-0473-y. Epub 2018 Feb 12.

28.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

PMID:
29330221
29.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

30.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.

Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.

31.

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP.

Am J Hematol. 2018 Feb;93(2):E49-E52. doi: 10.1002/ajh.24980. Epub 2017 Dec 4. No abstract available.

32.

Expression signatures of early-stage and advanced medaka melanomas.

Klotz B, Kneitz S, Regensburger M, Hahn L, Dannemann M, Kelso J, Nickel B, Lu Y, Boswell W, Postlethwait J, Warren W, Kunz M, Walter RB, Schartl M.

Comp Biochem Physiol C Toxicol Pharmacol. 2018 Jun;208:20-28. doi: 10.1016/j.cbpc.2017.11.005. Epub 2017 Nov 21.

PMID:
29162497
33.

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.

Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.

Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15.

34.

The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.

Buccisano F, Hourigan CS, Walter RB.

Curr Hematol Malig Rep. 2017 Dec;12(6):547-556. doi: 10.1007/s11899-017-0420-z. Review.

PMID:
29027628
35.

The Novel Evolution of the Sperm Whale Genome.

Warren WC, Kuderna L, Alexander A, Catchen J, Pérez-Silva JG, López-Otín C, Quesada V, Minx P, Tomlinson C, Montague MJ, Farias FHG, Walter RB, Marques-Bonet T, Glenn T, Kieran TJ, Wise SS, Wise JP Jr, Waterhouse RM, Wise JP Sr.

Genome Biol Evol. 2017 Dec 1;9(12):3260-3264. doi: 10.1093/gbe/evx187. Erratum in: Genome Biol Evol. 2018 Apr 1;10(4):1063.

36.

Fluorescent light exposure incites acute and prolonged immune responses in zebrafish (Danio rerio) skin.

Gonzalez TJ, Lu Y, Boswell M, Boswell W, Medrano G, Walter S, Ellis S, Savage M, Varga ZM, Lawrence C, Sanders G, Walter RB.

Comp Biochem Physiol C Toxicol Pharmacol. 2018 Jun;208:87-95. doi: 10.1016/j.cbpc.2017.09.009. Epub 2017 Sep 29.

PMID:
28965927
37.

Exposure to 4100K fluorescent light elicits sex specific transcriptional responses in Xiphophorus maculatus skin.

Boswell WT, Boswell M, Walter DJ, Navarro KL, Chang J, Lu Y, Savage MG, Shen J, Walter RB.

Comp Biochem Physiol C Toxicol Pharmacol. 2018 Jun;208:96-104. doi: 10.1016/j.cbpc.2017.09.008. Epub 2017 Sep 29.

PMID:
28965926
38.

Patient-reported outcomes in acute myeloid leukemia: Where are we now?

Buckley SA, Kirtane K, Walter RB, Lee SJ, Lyman GH.

Blood Rev. 2018 Jan;32(1):81-87. doi: 10.1016/j.blre.2017.08.010. Epub 2017 Sep 1. Review.

PMID:
28888621
39.

Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes.

Samuelson Bannow BT, Walter RB, Gernsheimer TB, Garcia DA.

J Thromb Thrombolysis. 2017 Nov;44(4):442-447. doi: 10.1007/s11239-017-1539-4.

40.

Quality of life from the perspective of the patient with acute myeloid leukemia.

Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee SJ.

Cancer. 2018 Jan 1;124(1):145-152. doi: 10.1002/cncr.30982. Epub 2017 Sep 7.

41.

Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Zhou Y, Wood BL, Walter RB, Becker PS, Percival ME, Bar M, Shaw C, Gardner K, Hendrie P, Abkowitz J, Appelbaum FR, Estey E.

Leukemia. 2017 Nov;31(11):2536-2537. doi: 10.1038/leu.2017.263. Epub 2017 Aug 18. No abstract available.

PMID:
28819284
42.

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.

J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23.

43.

Gemtuzumab ozogamicin in acute myeloid leukemia.

Godwin CD, Gale RP, Walter RB.

Leukemia. 2017 Sep;31(9):1855-1868. doi: 10.1038/leu.2017.187. Epub 2017 Jun 13. Review.

PMID:
28607471
44.

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.

45.

Transcriptome assembly and candidate genes involved in nutritional programming in the swordtail fish Xiphophorus multilineatus.

Lu Y, Klimovich CM, Robeson KZ, Boswell W, Ríos-Cardenas O, Walter RB, Morris MR.

PeerJ. 2017 May 2;5:e3275. doi: 10.7717/peerj.3275. eCollection 2017.

46.

Measurable residual disease testing in acute myeloid leukaemia.

Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB.

Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7. Review.

PMID:
28386105
47.

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Chen X, Othus M, Wood BL, Walter RB, Percival MM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.

Leuk Lymphoma. 2017 Nov;58(11):2717-2719. doi: 10.1080/10428194.2017.1307359. Epub 2017 Mar 28. No abstract available.

PMID:
28351184
48.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

49.

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.

Godwin CD, McDonald GB, Walter RB.

Blood. 2017 Apr 20;129(16):2330-2332. doi: 10.1182/blood-2017-01-762419. Epub 2017 Feb 2. No abstract available.

50.

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB.

Haematologica. 2017 May;102(5):865-873. doi: 10.3324/haematol.2016.159343. Epub 2017 Jan 25. Review.

Supplemental Content

Loading ...
Support Center